C4 Therapeutics, Inc. (CCCC)

NASDAQ: CCCC · USD

$3.43

+0.22 (+6.7%)· Recorded snapshot

Market cap	421.4M
Revenue (ttm)	35M
Net income (ttm)	-101.4M
EPS (ttm)	-$0.91
Shares out	123M
Volume	3,940,220
Beta	3.08

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 35M
Net income (ttm): -101.4M
EPS (ttm): -$0.91
Market cap: 421.4M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Giữ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-48.1

P25 n/aP50 n/aP75 n/a

ROIC-23.3

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CCCC indicators

Market & fundamental data

Available fields

208

Groups with data

Currency

USD

Showing 208 of 208 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001662579
Company name	C4 Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	12529R107
Earnings date	2026-11-09
Earnings time	bmo
Employees	104
Employees change	-6
Employees growth	-5.45%
Enterprise value	$177.8M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2015
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2020-10-02
Is primary listing	Yes
Is SPAC	No
ISIN number	US12529R1077
Last 10-K release date	2026-02-26
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$421.4M
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$3.43
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	CCCC
U.S. state	Massachusetts
Website	https://www.c4therapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-26.52%
EV/Sales	5.04x
FCF / EV yield	-48.37%
FCF yield	-20.33%
Forward EV/Sales	7.51x
Forward P/S	17.87x
P/B ratio	1.6x
P/S ratio	11.99x
Price / tangible book value	1.7x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-288.34%
EBITDA margin	-283.82%
Gross margin	86.34%
Operating margin	-288.34%
Pretax margin	-289.09%
Profit margin	-289.44%
Profit per employee	$-975,154
Revenue per employee	$336,913
ROA	-19.25%
ROA (5Y)	-17.74%
ROCE	-32.47%
ROE	-48.14%
ROE (5Y)	-40.46%
ROIC	-23.34%
SBC / revenue	40.83%
Tax / revenue	0.35%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	3
EPS growth years	2
Gross profit growth	105.56%
Net income growth quarters	3
Net income growth years	2
Revenue growth	2.33%
Revenue growth (Q)	2.75%
Revenue growth (QoQ)	7.95%
Revenue growth 3Y	29.78%
Revenue growth 5Y	0.65%
Revenue growth quarters	1
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-523,000
Depreciation and amortization	$1.6M
EBIT	$-101M
EBITDA	$-99.4M
EPS	$-0.91
FCF per share	$-0.69
Financing cash flow	$160.6M
Free cash flow	$-85.4M
Free cash flow minus SBC	$-99.7M
Gross profit	$30.3M
Income taxes	$121,000
Investing cash flow	$-75.3M
Net cash flow	$453,000
Net income	$-101.4M
Operating cash flow minus SBC	$-99.2M
Operating income	$-101M
Revenue	$35M
Stock-based compensation	$14.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-1.87
Book value per share	$2.01
Debt / equity	0.23
Long-term assets	$96.5M
Long-term liabilities	$63.9M
Net cash (debt)	$243.6M
Net cash / market cap	57.98%
Net cash growth	52.2%
Net debt / equity	-0.99
Piotroski F-Score	4
Property, plant and equipment	$41.8M
Shareholders' equity	$247.3M
Tangible book value	$247.3M
Tangible book value per share	$2.01
Total assets	$359.4M
Total cash	$253.7M
Total debt	$56.9M
Total liabilities	$112.1M
WACC	18.68%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.11
Current assets	$262.9M
Current liabilities	$48.2M
Current ratio	5.45
Net working capital	$-32.3M
Quick ratio	5.29
Working capital	$214.7M
Working capital turnover	0.18

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-58.3%
Dividend yield	0%
Shareholder yield	-58.3%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$3.47
1D price change	6.7%
1M price change	14.93%
1M total return	14.93%
1W price change	8.04%
1W total return	8.04%
1Y price change	29.25%
1Y return CAGR	29.27%
1Y total return	29.25%
20-day SMA	$2.99
200-day SMA	$3.20
3M price change	-4.6%
3M total return	-4.6%
3Y price change	146.4%
3Y return CAGR	35.06%
3Y total return	146.4%
50-day SMA	$3.36
50-day SMA vs 200-day SMA	50over200
52-week high	$5.17
52-week high date	2026-06-30
52-week low	$1.69
52-week low date	2026-02-05
5Y price change	-92.4%
5Y return CAGR	-40.27%
5Y total return	-92.4%
6M price change	21.03%
6M total return	21.03%
All-time high	$51.21
All-time high date	2021-09-23
All-time low	$1.06
All-time low date	2023-12-06
Average true range (ATR)	$0.22
Average volume	2.9M
Beta (1Y)	2.39
Beta (2Y)	2.35
Beta (5Y)	3.08
Change from 52-week high	-33.75%
Change from 52-week low	102.66%
Change from all-time high	-93.31%
Change from all-time low	223.11%
Change from open	5.38%
Day's gap	1.25%
Dollar volume	$13.5M
High price	$3.53
Low price	$3.23
Monthly RSI	47.67
Open price	$3.25
Position in 52-week range	65%
Premarket change	1.71%
Premarket close	$3.21
Premarket price	$3.27
Premarket volume	33.3K
Previous close	$3.21
Price vs 150-day SMA	-1.3%
Price vs 20-day SMA	14.43%
Price vs 200-day SMA	7.13%
Price vs 50-day SMA	2.09%
Relative volume	1.39
Return from IPO open	-87.16%
Return from IPO price	-82.03%
RSI	59.02
Sharpe ratio	0.66
Sharpe ratio (3Y)	0.68
Sharpe ratio (5Y)	0.03
Sortino ratio	1.18
Sortino ratio (3Y)	1.66
Sortino ratio (5Y)	0.12
Volume	3.9M
Weekly RSI	51.98
YTD price change	79.32%
YTD total return	79.32%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	94.5M
Float percentage	76.81%
Shares change (QoQ)	3.67%
Shares change (YoY)	58.3%
Shares held by insiders	1.04%
Shares held by institutions	86.71%
Shares outstanding	123M
Short % of float	42.75%
Short % of shares	32.84%
Short ratio	19.6 days

Deeper analysis on CCCC

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CCCC report

Is a complete CCCC research report available?

No complete published report is available for C4 Therapeutics, Inc. (CCCC) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

C4 Therapeutics, Inc. (CCCC)

Price

Financial snapshot

Fair-value bridge

Latest news · CCCC

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CCCC indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CCCC

Frequently asked questions